|
[1]YUEN MF,HOU JL,CHUTAPUTTI A.Hepatocelluar carcinoma in the Asia pacific region[J].J Gastroenterol Hepatol,2009,24(3):346-353.
|
|
[2]CHEN CJ,YU MW,LIAW YF.Epidemiological characteristics and risk factors of hepatocellular carcinoma[J].J Gastroenterol Hepatol,1997,12(9-10):s294-s308.
|
|
[3]BEASLEY RP.Hepatitis B virus as the etiological agent in hepatocellular carcinoma:epidemiological consideration[J].Hepatology,1982,2:21-26.
|
|
[4]PARK NH,CHUNG YH.Molecular mechanisms of hepatitis B virus-associated hepatocellular carcinoma[J].Korean J Hepatol,2007,13(3):320-340.
|
|
[5]McP ARTLAND JL,GUZAIL MA,KENDALL CH,et al.Apoptosis in chronic viral hepatitis parallels histological activity:an immunohistochemical investigation using anti-activated caspase-3 and M30 cytodeath antibody[J].Int J Exp Pathol,2005,68(1):19-24.
|
|
[6]LIU CJ,CHEN BF,CHEN PJ,et al.Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers[J].J Infect Dis,2006,193(9):1258-1265.
|
|
[7] LIAW YF,SUNG JJ,CHOW WC,et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl J Med,2004,351(15):1521-1531.
|
|
[8]SINGAL AK,SALAMEH H,KUO YF,et al.Meta-analysis:the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B[J].Aliment Pharmacol Ther,2013,38(2):98-106.
|
|
[9] Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.
|
|
[10]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960.
|
|
[11]EL-SERAG HB.Epidemiology of viral hepatitis and hepatocellular carcinoma[J].Gastroenterology,2012,142(6):1264-1273.
|
|
[12]CHEN CF,LEE WC,YANG HI,et al.Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma[J].Gastroenterology,2011,141(4):1240-1248.
|
|
[13]PAPATHEODORIDIS GV,LAMPERTICO P,MANOLAKOPOULOS S,et al.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy:a systematic review[J].J Hepatol,2010,53(2):348-356.
|
|
[14]MASUZAKI R,TATEISHI R,YOSHIDA H,et al.Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography[J].Hepatology,2009,49(6):1954-1961.
|
|
[15]XU WJ,GUO BL,HAN YG,et al.Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73 in hepatocellular carcinomas with low AFP levels[J].Tumour Biol,2014,35(12):12069-12074.
|
DownLoad: